What are the drug interactions and risks when combining baclofen with pregabalin (Lyrica)?

Baclofen and Lyrica (Pregabalin) Drug Interaction

Combining baclofen with pregabalin (Lyrica) significantly increases the risk of central nervous system (CNS) depression, including somnolence, respiratory depression, and coma, and this combination should be avoided or used with extreme caution with dose reductions, particularly in patients with any degree of renal impairment.

Mechanism and Risk Profile

Both medications work through GABAergic mechanisms—baclofen as a GABA-B agonist and pregabalin through N-type voltage-gated calcium channel inhibition—creating additive CNS depressant effects 1. The FDA label for Lyrica explicitly warns of post-marketing reports of respiratory failure and coma when pregabalin is combined with other CNS depressant medications 1.

Key Clinical Evidence

A 2025 case report documented synergistic CNS depression in a 68-year-old patient with only mild renal impairment (eGFR 77 mL/min) who received baclofen 30 mg/day plus pregabalin 300 mg/day, resulting in progressive somnolence leading to coma that resolved completely 48 hours after discontinuation 2. This demonstrates that even mild renal dysfunction amplifies the risk.

Animal studies confirm that pregabalin combined with baclofen causes significant cognitive deficits and impaired memory discrimination, effects not seen with either drug alone 3.

Clinical Management Algorithm

If combination therapy is absolutely necessary:

1. Dose Reduction is Mandatory

   • Start pregabalin at 25-50 mg/day (not standard doses) 4
   • Use lowest effective baclofen dose
   • Adjust both medications based on creatinine clearance, even with mild renal impairment 2

2. Monitor Intensively For:

   • Somnolence and altered mental status
   • Respiratory depression
   • Dizziness and falls (particularly in older adults) 4
   • Cognitive impairment and memory deficits 3

3. High-Risk Populations Requiring Extra Caution:

   • Any degree of renal impairment (both drugs are renally cleared) 2
   • Older adults (≥65 years) 4
   • Patients on concurrent opioids or benzodiazepines 5, 1
   • Those taking ≥3 CNS-active medications 5

Critical Pitfalls to Avoid

• Do not use standard starting doses when combining these medications—both require reduction 2
• Do not assume normal renal function is protective—the case report showed severe CNS depression with eGFR >75 mL/min 2
• Do not combine with opioids or benzodiazepines if at all possible, as the 2019 AGS Beers Criteria specifically warns against combining opioids with gabapentinoids 5, and the same principle applies to baclofen
• Recognize that pharmacokinetic interactions are minimal (pregabalin doesn't interact metabolically) 1, but pharmacodynamic interactions are severe 1, 2

Pharmacodynamic Considerations

The FDA label confirms that while pregabalin shows no pharmacokinetic interactions, it demonstrates additive effects on cognitive and gross motor functioning when combined with other CNS depressants 1. The combination with baclofen creates a particularly dangerous scenario because both enhance GABAergic inhibition through different mechanisms, producing synergistic rather than merely additive effects 2.

Bottom line: This combination carries substantial morbidity risk through CNS depression and falls. If both medications are deemed essential, initiate at 50-75% dose reduction for both agents, titrate slowly over weeks (not days), and maintain heightened surveillance for CNS adverse effects, regardless of baseline renal function.